Healix

Low Hospital Admission Rates Following Physician Office Infusion Center (POIC)-Based Outpatient Treatment with Intravenous Antibiotics

Authors:
Fernando S. Alvarado, MD, MPH, TM – Infectious Disease Consultants, Altamonte Springs, FL
Brian Metzger,MD – Austin Infectious Disease Consultants, Austin, TX
Richard M. Mandel, MD – Southern Arizona Infectious Disease Specialists, PLC, Tucson, AZ;
Richard C. Prokesch, MD,FACP, FIDSA – Infectious Diseases Associates, Riverdale, GA
Robin H. Dretler, MD,FIDSA – Infectious Disease Specialists of Atlanta, Decatur, GA
H. Barry Baker, MD, FACP – Infectious Disease Physicians, Miami, FL
Claudia P. Schroeder, PharmD, PhD – Healix Infusion Therapy, Sugar Land, TX
Lucinda J. Van Anglen, PharmD – Healix Infusion Therapy, Sugar Land, TX

View Poster View Abstract

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.

FacebookTwitterLinkedInarrow1arcsearchiconowdtnotfound